Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT03235648 Recruiting - Ovarian Cancer Clinical Trials

Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer

NCT ID: NCT03229122 Completed - Ovarian Cancer Clinical Trials

Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA

CHARLOTTE
Start date: December 26, 2016
Phase:
Study type: Observational [Patient Registry]

The multi-centered, cross-sectional investigations shall be conducted in this study with the objective of identifying the ownership ratio of gBRCAm on the newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer in Japan.

NCT ID: NCT03225989 Active, not recruiting - Colorectal Cancer Clinical Trials

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum 50 patients can be enrolled. LOAd703 is an immunostimulatory gene therapy using an selection replication competent adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper (TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.

NCT ID: NCT03219268 Completed - Ovarian Cancer Clinical Trials

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Start date: August 18, 2017
Phase: Phase 1
Study type: Interventional

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

NCT ID: NCT03219242 Enrolling by invitation - Ovarian Cancer Clinical Trials

Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology

CAIMAN
Start date: June 30, 2016
Phase: N/A
Study type: Interventional

Longitudinal prospective study on primary debulking surgery including bowel resection in advanced stage ovarian cancer patients using Caiman® technology

NCT ID: NCT03210298 Recruiting - Colorectal Cancer Clinical Trials

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

PIPACRegis
Start date: January 2016
Phase:
Study type: Observational [Patient Registry]

Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases. Indication is decided by the treating physician. There are no predefined inclusion or exclusion criteria.

NCT ID: NCT03206645 Completed - Ovarian Cancer Clinical Trials

Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy

PTC-001
Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is previously untreated.

NCT ID: NCT03205176 Completed - Breast Cancer Clinical Trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Start date: June 30, 2017
Phase: Phase 1
Study type: Interventional

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

NCT ID: NCT03203993 Terminated - Ovarian Cancer Clinical Trials

China Ovarian Cancer BRCA Testing Study

CRONUS
Start date: January 31, 2018
Phase:
Study type: Observational

This is a prospective, multi-center, observational study, the primary objective is to evaluate the prevalence of gBRCA/sBRCAm in newly diagnosed ovarian cancer patients and explore ovarian cancer treatment outcomes of different BRCAm status

NCT ID: NCT03197584 Withdrawn - Ovarian Cancer Clinical Trials

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Start date: December 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with epithelial ovarian cancer who have progressed on or after SoC therapy.